Propanc Biopharma (PPCB) Amortizatization of Intangibles (2014 - 2025)
Propanc Biopharma (PPCB) posted quarterly Amortizatization of Intangibles of $11843.0 for Q4 2025, down 84.55% year-over-year from $76661.0 in Q4 2024, and down 92.15% quarter-over-quarter from $150902.0 in Q3 2025.
Propanc Biopharma (PPCB) Amortizatization of Intangibles (2014 - 2025) Analysis & Trends
Propanc Biopharma (PPCB) has reported Amortizatization of Intangibles for 12 consecutive years, with $11843.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Amortizatization of Intangibles fell 84.55% year-over-year to $11843.0; the TTM figure through Dec 2025 stood at $28032.0 (down 96.36% YoY), while the FY2025 annual figure was $46985.0, down 84.02% from the prior year.
- Amortizatization of Intangibles declined to $11843.0 in Q4 2025 per PPCB's latest filing, from $150902.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $555543.0 in Q2 2024 and bottomed at -$146298.0 in Q2 2025.
- Historically, Amortizatization of Intangibles has averaged $86458.2 across 5 years, with a median of $41952.0 in 2022.
- Annual changes were most pronounced in 2022 — Amortizatization of Intangibles surged 6921.33% — and 2023, when it slumped 384.08%.
- Propanc Biopharma's Amortizatization of Intangibles stood at $5221.0 in 2021, then surged by 908.03% to $52629.0 in 2022, then jumped by 47.45% to $77604.0 in 2023, then fell by 1.22% to $76661.0 in 2024, then plunged by 84.55% to $11843.0 in 2025.
- Business Quant data shows PPCB's Amortizatization of Intangibles at $11843.0 in Q4 2025, $150902.0 in Q3 2025, and -$146298.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Propanc Biopharma | 587,855.41 | 587,855.41 | - | 35,875.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 11,843.00 |
| Dec 31, 2025 | 11,843.00 |
| Sep 30, 2025 | 150,902.00 |
| Sep 30, 2025 | 150,902.00 |
| Jun 30, 2025 | -146,298.00 |
| Jun 30, 2025 | -146,298.00 |
| Mar 31, 2025 | 11,585.00 |
| Mar 31, 2025 | 11,585.00 |
| Dec 31, 2024 | 76,661.00 |
| Dec 31, 2024 | 76,661.00 |
| Sep 30, 2024 | 56,983.00 |
| Sep 30, 2024 | 56,983.00 |
| Jun 30, 2024 | 555,543.00 |
| Jun 30, 2024 | 555,543.00 |
| Mar 31, 2024 | 81,708.00 |
| Mar 31, 2024 | 81,708.00 |
| Dec 31, 2023 | 77,604.00 |
| Dec 31, 2023 | 77,604.00 |
| Sep 30, 2023 | -88,846.00 |
| Sep 30, 2023 | -88,846.00 |